Hims & Hers Stock Jumps 40% on Novo Nordisk GLP-1 Partnership
Hims & Hers agreed to distribute Novo Nordisk’s branded Wegovy and Ozempic injectables plus the Wegovy pill on its telehealth platform at self-pay prices, ending a legal dispute over compounded GLP-1 drugs. Shares jumped over 40% as the agreement restores lawful GLP-1 offerings and bolsters Hims’s growth outlook.
1. Partnership Details
Hims & Hers signed an agreement with Novo Nordisk to offer branded Wegovy and Ozempic injectables along with the Wegovy oral pill on its telehealth platform at Novo’s self-pay prices, formally ending the February lawsuit over Hims’s compounded GLP-1 products.
2. Legal Resolution and Regulatory Impact
Under the deal, Hims will cease advertising compounded GLP-1 drugs while still providing them for rare, FDA-compliant cases, resolving both the legal dispute and the FDA’s planned enforcement against unauthorized weight-loss therapies.
3. Market Reaction and Financial Implications
Hims shares surged over 40% on the news, reflecting investor confidence in the restored ability to sell high-margin branded GLP-1 treatments and the potential for significant revenue growth from these weight-loss drugs.
4. Competitive Landscape
Novo Nordisk has driven over 600,000 Wegovy prescriptions since launch and cut obesity drug prices from about $1,000 to $149–$299 monthly, heightening competition with Eli Lilly and reinforcing telehealth as a key distribution channel.